Overview

A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)

Status:
Withdrawn

Trial end date:
2014-05-01

Target enrollment:

Participant gender:

Summary

This study will evaluate and compare the effectiveness of MK-0653 (Vytorin) to current standard treatment with other statins for the treatment of dyslipidemia in moderate, moderately-high and high-risk participants.

Phase:

Phase 4

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Ezetimibe
Ezetimibe, Simvastatin Drug Combination
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Simvastatin